[Tolerability, persistence and satisfaction. Retrospective cohort study in patients with overactive bladder syndrome treated with transdermal Oxybutynin under Standard ClinicAl pRactice. OSCAR Study.]

Arch Esp Urol 2017 Jul;70(6):561-569

Servicio de Urología. Hospital Universitario Puerta del Mar. Cádiz. España.

Objectives: To determine the tolerability, persistenceand satisfaction of patients with overactive bladder syndrome (OAB) treated with transdermal oxybutynin (OXY-TDS).

Methods: Observational, retrospective, multicenter study, in patients with OAB who had started treatment with OXY-TDS at least 12 months before their inclusion. Tolerability was evaluated by number, severity criteria, resolution type of adverse reactions, and cognitive function with Mini-Mental State Examination (MMSE), at 1 year of treatment. The patients who remained under treatment during the observation period were considered persistent. Patient satisfaction was evaluated using an ad hoc questionnaire.

Results: The clinical history of 105 patients was evaluated. 92.4% were women. The mean age of all the patients was 59.4 ± 11.8 years. After 12 months of treatment, dry mouth was present in 5.7% of patients and 27.6% had mild or moderate adverse reactions in the area of application. The persistence in treatment was 55.2%. The use of the OXY-TDS was considered comfortable or very comfortable by 92.9% of patients.

Conclusions: The study performed in patients with OAB shows that OXY-TDS provides low incidence of systemic adverse effects, including dry mouth, high persistence, improved adherence rates and high satisfaction of patients after one year of treatment.
July 2017
12 Reads

Publication Analysis

Top Keywords

patients
9
overactive bladder
8
study patients
8
bladder syndrome
8
patients oab
8
transdermal oxybutynin
8
treated transdermal
8
year treatment
8
patients overactive
8
dry mouth
8
adverse reactions
8
satisfaction patients
8
treatment
6
patients evaluated
4
months treatment
4
105 patients
4
clinical history
4
history 105
4
evaluated 924%
4
years months
4

Similar Publications

Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.

J Manag Care Pharm 2008 Apr;14(3):291-301

Xcenda, LLC, Cincinnati, OH 45255, USA. anna.dsouza

Background: Pharmacotherapy constitutes an important adjunct to behavioral therapy for the treatment of overactive bladder (OAB). Tolterodine and oxybutynin are commonly prescribed drugs for OAB treatment that exert their beneficial effect by suppressing bladder muscle contractions. However, high discontinuation rates have been observed for these drugs in clinical trials, as well as in real-world settings, in part due to adverse effects. Read More

View Article
April 2008

Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.

BJU Int 2007 Apr 20;99(4):836-44. Epub 2006 Dec 20.

Evanston Continence Center, Evanston Northwestern Healthcare, Northwestern University, Feinburg School of Medicine, Evanston IL, USA.

Objective: To assess health-related quality-of-life (HRQoL) and safety with the oxybutynin transdermal system (OXY-TDS) (Oxytrol), Watson Pharma, Corona, CA, USA) in the Multicentre Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin (MATRIX) study, as HRQoL measurements are increasingly important in evaluating pharmacotherapy for overactive bladder (OAB).

Patients And Methods: This randomized, open-label, community-based study enrolled 2878 participants aged >/=18 years who had been given a diagnosis of OAB. The 327 study sites were representative of various practice types. Read More

View Article
April 2007

Evolution of transdermal oxybutynin in the treatment of overactive bladder.

Int J Clin Pract 2008 Jan;62(1):167-70

Department of Urology, Brighton & Sussex University Hospitals NHS Trust, Brighton, UK.

Overactive bladder (OAB) syndrome affects millions of people worldwide. In addition to adversely affecting quality of life, the direct and indirect costs in managing patients with OAB incur a substantial financial burden on health services. Among the approved anticholinergics for treating OAB, oxybutynin is the most extensively studied drug in clinical trials. Read More

View Article
January 2008

[Maintenance of the efficacy of the oxybutynin patch for the treatment of overactive bladder syndrome despite the change in the area of application: study of four cases.]

Arch Esp Urol 2018 Jun;71(5):502-505

Servicio de Urología. Hospital de Poniente. El Ejido. Almería. España.

The transdermal route for administration of anticholinergic drugs can provide efficacy with less systemic adverse effects. The transdermal oxybutynin patch (OXYTDS) offers advantages over oral administration for patients treated for Overactive bladder (OAB) syndrome. The limited evidence on the OXY-TDS patch application areas of the skin, makes difficult counseling patients who require a change to skin zones other than those recommended by the manufacturer. Read More

View Article
June 2018